Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages

Abstract

Human respiratory syncytial virus (hRSV) infection is a leading cause of severe respiratory tract infections. Effective, directly acting antivirals against hRSV are not available.

Resveratrol inhibits respiratory syncytial virus replication by targeting heparan sulfate proteoglycans

“…For the purpose of our study, we divided this life cycle into two distinct phases: the binding phase, encompassing the first hour post-infection, and the entry/replication phase, spanning the subsequent 6-hour period after removing any remaining virions. 29,30 Our investigation revealed a significant reduction in viral RNA levels when resveratrol was present during one viral life cycle (Fig. 2a).…”

“…For the purpose of our study, we divided this life cycle into two distinct phases: the binding phase, encompassing the first hour post-infection, and the entry/replication phase, spanning the subsequent 6-hour period after removing any remaining virions. 29,30…”

“…To further investigate the impact of resveratrol on RSV binding, we conducted attachment assays in line with a previous study 29,30 (Fig. 2d).…”

Respiratory Syncytial Virus Infection: Treatments and Clinical Management

“… Targeting inflammatory molecules/anti-inflammatory molecules Danirixin (GSK1325756) RV568, (narrow spectrum kinase inhibitor) [ 20 , 21 , 27 , 50 , 51 , 54 , 58 , 79 ], 7. Prophylactics and immunoregulators MEDI 557 (recombinant human monoclonal antibody) MEDI 8897 (human RSV monoclonal antibody) RI-001 (polyclonal antibody) Motavizumab (MEDI-524), derived from palivizumab Trivalent nanobody ALX-0171 D25 RSV antibody (against F glycoproteins) (RSV-IVIG, RespiGam) intravenous immunoglobulin Palivizumab (humanized monoclonal IgG1 antibody) ALX-0171 (a nanobody preparation) REGN2222, (human monoclonal IgG1 antibody against RSV-F) MEDI-557 (derived from motavizumab) MEDI-8897, derived from D25-, an anti-RSV F MAb) [ 106 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 ] …”

Two synthetic steroid analogs reduce human respiratory syncytial virus replication and the immune response to infection both in vitro and in vivo

“…Palivizumab is a monoclonal antibody against HRSV approved for prophylactic treatment in high-risk children, its efficacy has been proven high but not complete [ 8 ] and its cost is prohibitive ([ 9 , 10 ]). Thus, there are no effective antivirals against HRSV until today [ 11 ].…”